HK1003422A1 - A method of treating liver disease and like indications with vasodilating agents - Google Patents

A method of treating liver disease and like indications with vasodilating agents

Info

Publication number
HK1003422A1
HK1003422A1 HK98102526A HK98102526A HK1003422A1 HK 1003422 A1 HK1003422 A1 HK 1003422A1 HK 98102526 A HK98102526 A HK 98102526A HK 98102526 A HK98102526 A HK 98102526A HK 1003422 A1 HK1003422 A1 HK 1003422A1
Authority
HK
Hong Kong
Prior art keywords
indications
liver disease
treating liver
vasodilating agents
liver
Prior art date
Application number
HK98102526A
Other languages
English (en)
Inventor
Allan Joseph Mcclean
Original Assignee
Pharmacy And Therapeutic Advis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacy And Therapeutic Advis filed Critical Pharmacy And Therapeutic Advis
Publication of HK1003422A1 publication Critical patent/HK1003422A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Electrotherapy Devices (AREA)
  • Medicines Containing Plant Substances (AREA)
HK98102526A 1993-09-08 1998-03-24 A method of treating liver disease and like indications with vasodilating agents HK1003422A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPM110493 1993-09-08
PCT/AU1994/000525 WO1995007080A1 (en) 1993-09-08 1994-09-05 A method of treating liver disease and like indications with vasodilating agents

Publications (1)

Publication Number Publication Date
HK1003422A1 true HK1003422A1 (en) 1998-10-30

Family

ID=3777184

Family Applications (1)

Application Number Title Priority Date Filing Date
HK98102526A HK1003422A1 (en) 1993-09-08 1998-03-24 A method of treating liver disease and like indications with vasodilating agents

Country Status (14)

Country Link
EP (1) EP0717625B1 (xx)
JP (1) JP3842815B2 (xx)
KR (1) KR100350156B1 (xx)
CN (1) CN1115151C (xx)
AT (1) ATE218869T1 (xx)
CA (1) CA2170289C (xx)
DE (1) DE69430807T2 (xx)
FI (1) FI961029A0 (xx)
HK (1) HK1003422A1 (xx)
IL (1) IL110888A (xx)
NO (1) NO960866L (xx)
NZ (1) NZ273242A (xx)
SG (1) SG49645A1 (xx)
WO (1) WO1995007080A1 (xx)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854233A (en) * 1993-09-08 1998-12-29 Pharmacy And Therapeutic Advisory Consultancy Ltd. Method of treating liver disease and like indications with vasodilating agents
US6174917B1 (en) 1993-09-08 2001-01-16 Pharmacy And Therapeutic Advisory Consultancy Ltd. Method of treating liver disease and like indications with vasodilating agents

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992004008A1 (en) * 1990-09-07 1992-03-19 Universidad De Alicante Composition for treating ocular pain
ZA923474B (en) * 1991-05-20 1993-01-27 Marion Merrell Dow Inc Diltiazem formulation

Also Published As

Publication number Publication date
NZ273242A (en) 2001-04-27
ATE218869T1 (de) 2002-06-15
CN1130874A (zh) 1996-09-11
IL110888A0 (en) 1994-11-28
IL110888A (en) 1999-07-14
CA2170289A1 (en) 1995-03-16
FI961029A (fi) 1996-03-06
JPH09502188A (ja) 1997-03-04
EP0717625A1 (en) 1996-06-26
DE69430807T2 (de) 2002-12-19
CN1115151C (zh) 2003-07-23
CA2170289C (en) 2001-05-08
SG49645A1 (en) 1999-10-19
WO1995007080A1 (en) 1995-03-16
FI961029A0 (fi) 1996-03-06
NO960866D0 (no) 1996-03-04
NO960866L (no) 1996-03-04
DE69430807D1 (de) 2002-07-18
EP0717625A4 (en) 1997-12-29
JP3842815B2 (ja) 2006-11-08
EP0717625B1 (en) 2002-06-12
KR100350156B1 (ko) 2003-02-14

Similar Documents

Publication Publication Date Title
DK0731699T3 (da) Fremgangsmåde til reduktion af legemsfedt i dyr ved indgivelse af konjugeret linolsyre
ES2191068T3 (es) Tratamiento profilactico y terapeutico de la sensibilizacion e irritacion de la piel.
MX9504415A (es) Eteres antivirales de isoesteres de sustrato de proteasa de aspartato.
GB2357969A (en) Improvements in or relating to the treatment of lesions
IT8522574A0 (it) Composizione farmaceutica eprocedimento per trattare il corpo umano con essa.
HU9602937D0 (en) Compositions comprising dna damaging agents and p53
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
FI19991893A (fi) Säädellysti budesonidia vapauttava oraalisesti annettava koostumus ja budesonidin käyttö
EP0681475A4 (en) THERAPEUTIC INHIBITOR OF SMOOTH VASCULAR MUSCLE CELLS
DE69116380D1 (de) Pharmazeutische zubereitung zur behandlung verlängerter gerinnungszeit
EE9900428A (et) Köhavastased ravimkoostised
DE69800859T2 (de) Verwendung von Moxonidin zur Behandlung neuropathischer Schmerzen
HK1037980A1 (en) Use of selegiline or desmethylselegiline for the manufacture of a medicament for treating wounds, burns or photodamage.
HK1003422A1 (en) A method of treating liver disease and like indications with vasodilating agents
AR003979A1 (es) Administracion transdermica de vorozol.
GR3032224T3 (en) Therapeutic agent for threatened abortion.
KR100488038B1 (ko) 기관 보호 활성을 지닌 신규한 신체 보호 화합물 펩티드염, 이의 제조 방법 및 치료에서의 이의 용도
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
BR9708037A (pt) Método para o tratamento de abuso de substância
EP0539516A4 (xx)
PL325557A1 (en) Agent for use in prophylactics and/or treatmet of human and animal hair loss
UA19596A (uk) Спосіб лікуваhhя гіпертоhічhої хвороби гірудорефлексотерапією
ATE96020T1 (de) Hautbehandlungsmittel.

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20060905